3 Penny Stocks For Your Watchlist After a Bearish Trading Day
There’s a lot of debate surrounding penny stocks – whether they’re actually worth investing in, or if they’re just an easy way to make quick money. So, what’s the verdict? Are penny stocks worth buying?
One of the main reasons that investors lean toward penny stocks is the price. At under $5, there are options for every investor and budget. At under $5, you can buy a large quantity of penny stocks for a relatively small investment. Now, on the other hand, penny stocks are highly volatile. This can be a major benefit for some or a downside for others.
So, the best way to go about it is to understand your investing style and what your goals are. Considering this, let’s take a look at three penny stocks that could be worth adding to your watchlist after the day took a bearish turn.
3 Penny Stocks to Add to Your Watchlist Right Now
Clovis Oncology Inc. (NASDAQ: CLVS)
One of the bigger gainers of the day and a company that we have covered multiple times in the past few weeks is CLVS stock. At EOD, shares of CLVS had climbed by over 8.8% which is no small feat. If that doesn’t seem like a lot, in the past five days, we’ve seen CLVS stock climb by over 75% and by more than 97% in the past month period. These are major gains that reflect the bullish sentiment surrounding CLVS stock right now.
So, why is Clovis Oncology stock climbing right now? Well, the main reason comes as the company announced that it would seek FDA approval for its ovarian cancer drug only a week or so ago. This caused shares of CLVS stock to skyrocket by over 40% on the day it was announced. In the study, the company states that its drug, which is known as Rubraca, greatly improved survival rates in women with ovarian cancer.
In the Phase 3 trial, Clovis enrolled 538 women, and it plans to seek this approval in both the U.S. and Europe this year. With any biotech penny stock, big news like this is crucial for investors to consider. While it’s tough to say how long it will be until this compound is fully commercialized, there’s no doubting the importance of this announcement. Considering that, will it be on your penny stocks watchlist or not?
ADMA Biologics Inc. (NASDAQ: ADMA)
With over 2.9% in gains at EOD on April 5th, ADMA is another penny stock that investors are watching right now. In the past five day and one month periods, shares of ADMA stock have shot up by over 14% and 25% respectively. And, over the last six months, we’ve seen ADMA stock climb by more than 85%. While it’s common to see biotech stocks shoot up in short periods of time, long and steady gains are not as common.
This is one of the reasons that investors seem to like ADMA stock right now. But, why are shares of ADMA Biologics climbing? Well, the most recent news from the company came on March 25th. On the 25th, it stated that it received FDA approval for the extended shelf life of ASCENIV and BIVIGAM from 24 to 36 months. This makes it commercially available to U.S. healthcare providers immediately.
“The extension of ASCENIV’s and BIVIGAM’s shelf life to 36 months dating is a meaningful enhancement of each product’s go-to-market offering as it should provide for a more efficient networking capital cycle for the Company as well as allow for more versatile utilization and inventory management by providers.
The approval represents an important milestone as it pertains to the culmination of remediation initiatives enacted since ADMA acquired the Boca Raton, FL manufacturing facility in 2017.”The President and CEO of ADMA Biologics, Adam Grossman
Following this big news, it’s clear that investors are excited about the future trajectory of ADMA stock. Whether this makes it worth adding to your list of penny stocks to buy however, is up to you.
Aditxt Inc. (NASDAQ: ADTX)
At EOD on April 5th, shares of ADTX stock managed to shoot up by more than 4.3%. This is a big gain for the company and gives it a five day and one-month uptick of more than 10% and over 30% respectively. The biggest update for the company today came as it announced that it had signed into a revenue-sharing agreement with Cellvera for up to $30 million. The company states that this agreement should help to drive revenue growth in 2022 as well as security for its $14.5 million loan.
“Our potential acquisition of Cellvera will anchor Aditxt’s antimicrobial business segment. This agreement is an intermediate step in the acquisition process while we are proceeding with our due diligence for the overall transaction, and will be a key part of our revenue and growth strategy starting in 2022.”The Co-Founder and CEO of Aditxt, Amro Albanna
If you’re not familiar, Aditxt is a biotech penny stock working on technology for mapping and reprogramming the immune system. The company is a cutting edge player in the industry and continues to change the way that immune disorders and allergies are treated. Considering this exciting news, do you think ADTX stock is a worthwhile buy or not?
Can Penny Stocks Continue to Make Gains?
Finding the best penny stocks to buy is a mixture of understanding your own investing style and what is going on in the market.
While it can be and is challenging to find the best penny stocks to buy for you, knowing how to make money with small-caps is a major plus. So, always remember what your short and long-term trading goals are and how to maximize those. Considering this, do you think that penny stocks can continue to make gains this month?